MYLIN
For too long, rich neurological data been lost in the noise—buried beneath outdated tools, manual workflows, and the need for specialist interpretation.
Traditional EEG remains slow, subjective, and largely confined to narrow use cases like sleep studies and seizure monitoring—leaving its full clinical potential untapped.
We're changing that.
MYLIN transforms signal-rich but historically underutilized EEG into a powerful platform for biomarker extraction, therapeutic development, and clinical insight. It reveals patterns invisible to the human eye, surfacing novel neurological biomarkers that support earlier diagnosis, real-time treatment monitoring, and objective measurement of therapeutic response.
Raw Data to Real Insights.
Powered by AI, MYLIN delivers actionable insights from resting-state EEG, quickly and at scale.
Trained on thousands of EEG scans from leading partner institutions, it autonomously detects patterns linked to neurodegeneration, psychiatric conditions, and broader brain function.
Fast. Objective. Actionable.
This is EEG, Evolved.
Biomarkers:
Decoding the Brain
Neural biomarkers offer an objective window into how the brain functions and changes over time.
From oscillatory rhythms to network connectivity, these signals can reveal early signs of disease, track treatment response, and differentiate between complex neuropsychiatric conditions.
Pharma / Biotech
MYLIN offers a scalable, noninvasive solution for advancing CNS research. Enabling target engagement validation, patient population stratification, and development of robust endpoints for neuroactive compounds.
What once required costly, time-consuming imaging or indirect behavioral assessments can now be tracked directly through the brain’s electrical activity—with millisecond precision and at population scale.
Neurodegeneration Assessment
Alzheimer’s and Parkinson’s are often diagnosed late and tracked with imprecise, invasive tools. MYLIN changes that by capturing high-resolution, longitudinal brain activity—enabling earlier detection, objective monitoring of disease progression, and clear measurement of treatment response.
Our cloud-based platform scales easily, enabling population-level screening and proactive brain health management.